Skip to main content
. 2015 Feb 12;8:413–419. doi: 10.2147/OTT.S73366

Table 1.

HMGB1 levels and clinicopathological parameters in patients with breast cancer

n Tissue HMGB1, n
Serum HMGB1
Low High χ2 P-value ng/mL t-value P-value
Age, years ≤50 32 9 23 0.0683 0.7938 4.84±2.31 0.7160 0.4771
>50 24 6 18 4.36±2.76
Menopause Yes 25 8 17 0.6261 0.4288 4.32±2.57 0.8452 0.4017
No 31 7 24 4.89±2.46
HER-2/neu Negative 41 12 29 0.4810 0.4879 4.42±2.40 0.9916 0.3258
Positive 15 3 12 5.12±2.80
Tumor diameter ≤2 cm 30 10 20 1.4125 0.2346 4.51±2.55 0.4114 0.6824
>2 cm 26 5 21 4.79±2.49
Axillary lymph node metastasis Negative 31 12 19 5.0344 0.0248* 4.34±2.36 0.9878 0.3277
Positive 25 3 22 5.00±2.67
Differentiation grade High 18 10 8 11.1957 0.0008* 4.17±2.51 0.9148 0.3644
Intermediate/low 38 5 33 4.83±2.51
TNM stage 0, I, II 37 13 24 3.8766 0.0490* 4.55±2.41 0.3596 0.7206
III, IV 19 2 17 4.81±2.73

Note:

*

P<0.05.

Abbreviations: TNM, tumor-node-metastasis; HMGB1, high mobility group box-1.